Black Diamond Therapeutics, Inc. (BDTX)
Market Cap | 236.82M |
Revenue (ttm) | n/a |
Net Income (ttm) | -79.79M |
Shares Out | 56.25M |
EPS (ttm) | -1.66 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 522,880 |
Open | 4.710 |
Previous Close | 4.700 |
Day's Range | 4.190 - 4.810 |
52-Week Range | 1.620 - 7.660 |
Beta | 2.51 |
Analysts | Strong Buy |
Price Target | 12.00 (+185.04%) |
Earnings Date | Aug 9, 2024 |
About BDTX
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF Mas... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for BDTX stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 185.04% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/d/c/press2-2457512.jpg)
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment
![](https://cdn.snapi.dev/images/v1/g/g/conf15-2451339.jpg)
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m...
![](https://cdn.snapi.dev/images/v1/g/f/press6-2420543.jpg)
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
CAMBRIDGE, MA, May 09, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic muta...
![](https://cdn.snapi.dev/images/v1/q/z/press18-2389323.jpg)
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
![](https://cdn.snapi.dev/images/v1/z/s/press11-2366991.jpg)
Black Diamond Therapeutics Announces Changes to Board of Directors
CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...
![](https://cdn.snapi.dev/images/v1/a/o/press5-2360158.jpg)
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R ...
![](https://cdn.snapi.dev/images/v1/v/n/conf17-2354010.jpg)
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families...
![](https://cdn.snapi.dev/images/v1/l/c/press9-2319739.jpg)
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company focused on the development of MasterKey therapies to treat patie...
![](https://cdn.snapi.dev/images/v1/j/v/press6-2309657.jpg)
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
Abstract accepted for oral presentation on the evolving EGFR mutational landscape in NSCLC and MasterKey profile of BDTX-1535 addressing a broad spectrum of mutations Abstract accepted for oral presen...
![](https://cdn.snapi.dev/images/v1/v/1/press13-2298239.jpg)
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...
![](https://cdn.snapi.dev/images/v1/3/b/press15-2216234.jpg)
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC
![](https://cdn.snapi.dev/images/v1/y/x/press11-2194186.jpg)
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
Initial results show promising clinical activity in heavily pretreated patients 22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and 5 p...
![](https://cdn.snapi.dev/images/v1/p/g/press15-2141265.jpg)
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. and NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families ...
![](https://cdn.snapi.dev/images/v1/y/z/press13-2103647.jpg)
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes
![](https://cdn.snapi.dev/images/v1/m/u/conf16-2089958.jpg)
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families ...
![](https://cdn.snapi.dev/images/v1/8/m/press15-2066891.jpg)
Black Diamond Therapeutics Announces CEO Transition
Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept.
![](https://cdn.snapi.dev/images/v1/m/h/press6-2057276.jpg)
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
Company to present BDTX-1535 dose escalation data in NSCLC at the AACR-NCI-EORTC Conference in October 2023
![](https://cdn.snapi.dev/images/v1/5/e/press8-2019231.jpg)
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. and NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target...
![](https://cdn.snapi.dev/images/v1/v/a/press3-1954490.jpg)
Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target ...
![](https://cdn.snapi.dev/images/v1/j/j/press20-1952261.jpg)
Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. and NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target...
![](https://cdn.snapi.dev/images/v1/w/l/press16-1949101.jpg)
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
CAMBRIDGE, Mass. and NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target...
![](https://cdn.snapi.dev/images/v1/s/f/press7-1931632.jpg)
Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer
CAMBRIDGE, Mass. and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies de...
![](https://cdn.snapi.dev/images/v1/u/m/conf10-1918352.jpg)
Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies de...
![](https://cdn.snapi.dev/images/v1/h/s/press13-1878971.jpg)
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. and NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies des...
![](https://cdn.snapi.dev/images/v1/r/u/conf18-1841192.jpg)
Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
CAMBRIDGE, Mass. and NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies d...